- Scott Canute, Former President of Global Manufacturing at Eli Lilly and Company and Subsequently at Genzyme Corporation, Appointed New Board Member -
- Flexion CEO Michael Clayman Offers Thanks to Departing Board Member Andrew Schwab -
BURLINGTON, Mass., March 6, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) announced today recent changes to its Board of Directors. Scott Canute has been appointed to the Board of Directors, effective March 4, 2015. Mr. Canute was the former President of Global Manufacturing Operations at Eli Lilly and Company and subsequently the President of Global Manufacturing and Corporate Operations at Genzyme Corporation. In addition, Flexion Board of Directors member Andrew Schwab, 5AM Ventures, has stepped down from the Board.
"Scott, a seasoned pharmaceutical manufacturing operations executive, is a welcomed addition to the Flexion Board of Directors as we advance towards filing a new drug application and commercial launch of our lead drug candidate FX006," said Michael Clayman, M.D., President and CEO of Flexion Therapeutics. "With Scott's deep expertise in manufacturing late-stage and commercial pharmaceutical products, we look forward to him making important contributions as we progress our pipeline of drug candidates."
"I'd also like to thank Andy for his years of service and many contributions to Flexion Therapeutics," said Dr. Clayman. "He has played a critical role in the success of Flexion, has been a committed and highly valued Board member since 2009, and will be sincerely missed."
Mr. Canute spent 25 years at Eli Lilly and Company, ultimately serving as President, Global Manufacturing Operations from 2004 until 2007. In this capacity, he directed all manufacturing and supply chain activities for Lilly's global operations. Following his distinguished career at Lilly, he served as President of Global Manufacturing and Corporate Operations at Genzyme Corporation from 2010 until 2011. In this role, Mr. Canute served as the architect and leader of the organizational evolution that resulted in the supply of life-saving products to patients in need. Mr. Canute currently serves as a member of the Board of Directors of Oncobiologics, Inc. and the Technology Advisory Board of Moderna Therapeutics.
"I am honored to join the Flexion Board of Directors at this pivotal and exciting time for the Company, as it continues to advance FX006 towards potential approval and product launch," said Mr. Canute.
About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of local, injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, FX006, is an intra-articular sustained-release steroid in development for patients with moderate to severe Osteoarthritis, or OA, pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.
Media Contact Jamie Lacey-Moreira PressComm PR, LLC T: 410-299-3310 Corporate Contact Lisa Davidson, MBA Vice President, Finance and Administration Flexion Therapeutics, Inc. T: 781-305-7765
